Maintenance Therapy

Maintenance Therapy

Maintenance therapy is common in chronic disease care: medication continues after an initial induction or dose-escalation phase to keep the benefits it delivered. In obesity, it means staying on an obesity drug after the weight-loss phase to prevent regain. This treats obesity as a chronic, relapsing condition whose underlying biology does not go away with a short course of treatment, much like hypertension or type 2 diabetes, which also need long-term medication.

The case for maintenance therapy in obesity rests on how the body regulates energy. After weight loss, metabolic adaptation and hormonal pushback create a strong biological drive to regain weight. Staying on medication helps counter this by keeping appetite suppressed, protecting gains in metabolic rate and preserving the helpful hormonal changes created during active treatment. Evidence across incretin drugs consistently shows that stopping treatment leads to substantial regain, which underlines the need for long-term treatment plans.

Maintenance matters especially for retatrutide, given the record weight loss seen in Phase 2 trials. Questions being studied include whether a lower maintenance dose can hold the weight loss achieved during dose escalation, whether periodic treatment cycles could work, and how long continuous treatment should last. The Phase 3 TRIUMPH program should provide data on how well results hold up over time, and future trials may test step-down dosing that balances lasting efficacy against drug exposure and cost.